Completed
Phase 3
Age: 18Years - 65Years
All Genders
ID00395135
BLOOM Behavioral Modification and Lorcaserin for Overweight and Obesity Management A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients
Led by Eisai Inc. · Updated on 2019-10-02
3182
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)
CONDITIONS
Brief Title
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
Inclusion Criteria:
- Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea)
- Ability to complete a 2 year study
Exclusion Criteria:
- Diabetes
- Pregnancy
- History of heart valve disease
- Serious or unstable current or past medical conditions
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here